Management of Metastatic Urothelial Carcinoma in Emerging Markets (EM): An Expert Opinion

•There is a rise in incidence of urothelial carcinoma (UC) in the Emerging Markets (EM) region.•There is paucity of literature on frequency of patient eligibility and ineligibility for platinum-based chemotherapy from the EM region.•Common challenges for management of UC in EM includes cost of the therapies and lack of local guidelines or clinical guidance.•There is a low rate of participation in clinical trials from EM countries and LMICs in general as opposed to high income countries.